Life Technologies said this week that the US Food and Drug Administration has cleared its SeCore HLA typing assay and its 3500 Dx Genetic Analyzer, a Sanger sequencing instrument, for diagnostic use. The 510(k) clearance is a first for a sequencing system and sequencing-based assay, and the company's president of medical sciences, Ronnie Andrews, said that it "validates Life's move into diagnostics" as the company aims to bring additional products, such as its QuantStudio Dx real-time PCR system and Ion Torrent PGM, through 510(k) clearance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.